Cytori Therapeutics Inc (NASDAQ:CYTX) is scheduled to be announcing its earnings results after the market closes on Thursday, November 9th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.02). The company had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.23 million. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The company’s quarterly revenue was down 18.2% compared to the same quarter last year. During the same period last year, the business earned ($0.43) EPS. On average, analysts expect Cytori Therapeutics to post $-0.47 EPS for the current fiscal year and $-0.16 EPS for the next fiscal year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. lifted its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 612,304 shares of the biotechnology company’s stock after purchasing an additional 275,653 shares during the quarter. Vanguard Group Inc. owned about 1.89% of Cytori Therapeutics worth $674,000 as of its most recent filing with the SEC. 11.84% of the stock is owned by hedge funds and other institutional investors.

Several analysts have commented on CYTX shares. ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Tuesday, July 11th. Maxim Group set a $10.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a report on Monday, July 10th. Finally, B. Riley cut Cytori Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, July 25th.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Earnings History for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with's FREE daily email newsletter.